Spanish ultrasonic technology SME contributing precision micro-manufacturing and biomedical ultrasound expertise to European research consortia.
Ultrasion is a Spanish technology SME based near Barcelona (Cerdanyola del Vallès, adjacent to the UAB research campus) that specializes in ultrasonic processing technologies. Their H2020 track record shows two distinct application domains: ultrasound-assisted precision micro-manufacturing, and biomedical ultrasound — likely ultrasound-mediated delivery or device manufacturing in the context of protein therapies for neurological conditions. As a small industrial specialist, they contribute applied ultrasonic know-how to research consortia rather than leading them, filling the role of technology provider or industrial demonstrator. Their geographic location near a major Catalan research hub suggests close ties to academic spin-out culture and technology transfer.
MICROMAN (2015–2019) was a zero-defect net-shape micro-manufacturing training network where Ultrasion contributed industrial ultrasonic process expertise alongside academic and research partners.
OPTOGENERAPY (2017–2020), an RIA project on optogenetic protein therapy for Multiple Sclerosis, included Ultrasion as a funded participant — likely for ultrasound-assisted delivery, cell membrane permeation, or manufacturing of therapeutic components.
MICROMAN's explicit focus on 'process fingerprint' and zero-defect outcomes aligns with industrial quality assurance using ultrasonic sensing or monitoring during micro-scale forming and machining.
Ultrasion's two H2020 projects span 2015 to 2020, both active concurrently from 2017, making a clean early-to-late narrative difficult to draw. Their initial engagement (MICROMAN, 2015) was firmly in precision manufacturing — process control, zero-defect micro-forming, industrial training networks. By 2017 they had expanded into biomedical research (OPTOGENERAPY), suggesting that ultrasonic technology's cross-domain applicability was opening doors into life sciences. With no post-2020 H2020 projects visible, whether this biomedical direction became a sustained focus or a one-off experiment cannot be confirmed from available data.
If the OPTOGENERAPY participation reflects a deliberate strategic move, Ultrasion appears to be expanding ultrasonic technology applications from industrial manufacturing into biomedical and therapeutic fields — a direction with growing commercial potential.
Ultrasion has never held a coordinator role across their H2020 history — they consistently join as partner or participant, functioning as a specialist technology contributor within larger consortia. MICROMAN, as an MSCA-ITN training network, typically involves 10–15 partners across Europe, meaning Ultrasion has experience working inside complex multi-institution setups with mixed academic-industrial membership. This suggests they are comfortable as one voice among many and bring a specific industrial capability that complements research-heavy consortia.
Despite only two projects, Ultrasion has accumulated 33 unique consortium partners across 12 countries — a large network footprint explained by MICROMAN's broad ITN structure. Their collaborations are European in scope with no visible concentration in any single country beyond Spain.
Ultrasion occupies a rare position as an industrial SME with demonstrated expertise in both precision manufacturing (ultrasonic micro-machining and process control) and biomedical research applications — two sectors where ultrasonic technology increasingly intersects. For consortium builders in either manufacturing or life sciences seeking an applied industrial partner with ultrasound expertise from Spain, there are few SMEs of this type visible in the H2020 data. Their proximity to Barcelona's research ecosystem (UAB, ICMAB, CRG) also makes them a practical bridge between academic discovery and industrial application.
